Depression Tx Flashcards
Risk of Depression Recurrence
-1 episode: 50-60%
-2: 70%
-3: 90%
Pathologies related to depression
-stroke
-CHRONIC PAIN (fibromyalgia, low back/pelvic pain, bone/disease pain)
-mulitple sclerosis
-hypo/hyper thyroidism
-traumatic brain injury (TBI)
Recurrence
-risk becomes lower over time as duration of remission inc
-persistent mild sx during remission is a predictor of recurrence
-function deteriorates during episode and goes back to baseline upon remission
DSM-5 diagnosis
-at least one sx must be depressed mood or loss of interest/pleasure in doing things
DSM-5 diagnostic mnemonic (SIGE CAPS)
-Sleep (+/-)
-Interest dec
-Guilt/worthlessness
-Energy loss
-Concentration probs
-Appetite change (+/-)
-Psychomotor agitation/retardation
-Suicidal ideation
Self-admin rating scales
-Patient Health Questionnaire (PHQ-9): develped for primary care setting
-Mood Disorder Questionnare (MDQ): can rule out bipolar
Goals of depression tx
- reduce or eliminate sx
- restore functioning to baseline
- Reduce risk of relapse/recurrence
- Reduce suicide
How to choose drugs
-efficacy similar
-pt preference, response
-safety, cost, etc
Phase of depression tx
-acute: 6-12 weeks or remission of sx (induce remission)
-continuation: 4-9 months (recomended for all pt to prevent relapse)
-maintenance: pt specific duration, indefinite if >3 major, prevent recurrence
Risk of suicide
-boxed warning for suicide in ALL antidepressant meds for pt < 24 yeRA
Pharmacologic Classes
-SSRI
-SNRI
-TCA
-MAOis
-newer agents
-augmentation
SSRI drugs
-Citalopram
-Escitalopram
-Fluoxetine
-Fluvoxamine
-Paroxetine
-Sertraline
Citalopram
-dose-dependednt QTc prolongation
-substrate of 2C19 and 3A4
Fluoxetine
-long half-life (96-144h)
-activating potential
-2D6 and 3A4 inhibitor
-weight loss
Fluvoxamine
-1A2 and 2C19 inhbitor
Paroxetine
-MUST taper due to anticholinergic effects
-wt gain
-sedation
-septal wall defect risk to fetus
-2D6 and 2B6 inhibitor
Sertraline
-more GI upset than other antidepressants
SSRI adverse effects
-inc bleeding risk (platelet inhibition)
-weight gain (paroxetine)
-hyponatremia (esp in elderly)
-weight loss (fluoxetine)
-sexual dysfunction
SNRI drugs
-Desvenlafaxine
-Duloxetine
-Levomilnacipran
-Milnacipran
-Venlafaxine
Desvenlafaxine
-active metabolite of venlafaxine
-dose-limiting side effect: nausea
-no major CYP interactions
Duloxetine
-nausea
-FDA warning for hepatotoxicity
-2D6 inhibitor
-obtain LFTs at baseline and when sx or q6months
Levomilnacipran
-MUST adj renal impairment or strong 3A4 inhibitors
-3A4 substrate
Venlafaxine
-must be >150mg/day to have NE effects
-2D6 inhibitor at higher doses
SNRI adverse effects/key pearls
-BP elevation
-Nausea
-useful in pain syndrome, musculoskeletal pain, fibromyalgia, neuropathic pain